Business Context and Reporting Period
This Form 8-K is a current report filed by Liminatus Pharma, Inc. (Nasdaq: LIMN) on August 14, 2025. The Company is an emerging growth company focused on immuno-oncology therapies. The report primarily serves to disclose a development update regarding IBA101, the Company's CD47 checkpoint inhibitor.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate event rather than a financial statement.
Material Changes
The material change reported is the provision of an update on the development status of IBA101. No financial or operational changes compared to a prior period are detailed in this specific filing text.
Guidance, Outlook, and Risks
- Development Update: The Company provided an update on IBA101, furnished as Exhibit 99.1.
- Forward-Looking Statements: The Company expressly disclaims any obligation to release future updates or changes in expectations regarding forward-looking statements, except as required by law.
- Legal Status: The information in Item 7.01 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, meaning it is not subject to the same liability standards as filed financial data.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific details of the IBA101 development update.
- Verify the Company's current cash runway and liquidity status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor subsequent filings for any changes to the development timeline or clinical trial results for IBA101.
- Confirm the trading status of Common Stock (LIMN) and Warrants (LIMNW) on Nasdaq.